AI Issuer Brief
ClaudeLoading cached brief…
Price change · trailing returns
Live · FMP| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.98% | -3.40% | +8.74% | -4.12% | +13.25% | +12.79% | +55.70% | +7.53% | +65.60% | +121.29% | +29927.57% |
Aftermarket
Live · FMPLast trade
$118.60
53 sh
Bid
$118.52
10 sh
Ask
$118.60
40 sh
Spread
$0.080
Fair value
Football field →Weighted blend
$135.72
+14.32% vs spot
Recommendation
Buy
19 of 20 methods
Method spread
6bull13bear
±5% threshold
Analyst PT consensus: $129.31 (+8.92%)
Total assets
$136.87B
Total debt
$50.53B
Cash & equiv
$14.57B
Operating CF
$16.47B
Free cash flow
$12.36B
Buybacks
-$5.08B
Analyst view
DB · price_targets + analyst_gradesConsensus target
$129.31
+8.92% upside
Low
$100.00
Median
$133.00
High
$150.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?zacks.com·May 13, 2026
- Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026businesswire.com·May 12, 2026
- Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026businesswire.com·May 12, 2026
- Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoatebusinesswire.com·May 07, 2026
- Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Riskfxempire.com·May 04, 2026
- Merck: 'Strong Buy' - Terns Acquisition And Ability To Counter Keytruda Patent Lossseekingalpha.com·May 03, 2026
- Merck's LOE Risks Mitigated - R&D And M&As Are Paying Offseekingalpha.com·May 02, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $16.29B | -$4.24B | $-1.72 |
| Q4 Dec 2025 | $16.32B | $2.96B | $1.19 |
| Q3 Sep 2025 | $17.18B | $5.79B | $2.32 |
| Q2 Jun 2025 | $15.8B | $4.43B | $1.76 |
| Q1 Mar 2025 | $15.62B | $5.08B | $2.01 |
| Q4 Dec 2024 | $15.62B | $3.74B | $1.48 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Guindo Chirfi officer: Chief Marketing Officer | Sell | 10,000 | $1.21M | Feb 12, 2026 |
Li Dean Y officer: Executive VP & President, MRL | Sell | 10,235 | $1.2M | Feb 10, 2026 |
Zachary Jennifer officer: EVP, General Counsel | Sell | 38,835 | $4.63M | Feb 09, 2026 |
Guindo Chirfi officer: Chief Marketing Officer | Sell | 10,000 | $1.18M | Feb 09, 2026 |
Oosthuizen Johannes Jacobus officer: President, U.S. Market | Sell | 15,000 | $1.83M | Feb 06, 2026 |
DeLuca Richard R. officer: EVP&Pres, Merck Animal Heallth | Sell | 37,685 | $4.56M | Feb 06, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $64.93B | $23.49B | $18.25B | $7.28 | +28.12% |
| FY 2024 | $64.17B | $20.22B | $17.12B | $6.74 | +26.68% |
| FY 2023 | $60.12B | $2.95B | $365M | $0.14 | +0.61% |
| FY 2022 | $59.28B | $18.28B | $14.52B | $5.71 | +24.49% |
| FY 2021 | $48.7B | $13.2B | $13.05B | $5.14 | +26.79% |